Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy

Arthritis Care and Research

Volumn 67, Issue 5, 2015, Pages 731-736

  Yun, Huifeng ^a   Xie, Fenglong ^a   Delzell, Elizabeth ^a   Chen, Lang ^a   Levitan, Emily B ^a   Lewis, James D ^b   Saag, Kenneth G ^a   Beukelman, Timothy ^a   Winthrop, Kevin ^c   Baddley, John W ^a   Curtis, Jeffrey R ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; INFLIXIMAB; RITUXIMAB; TOCILIZUMAB; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; VARICELLA ZOSTER VACCINE;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HERPES ZOSTER; HISPANIC; HUMAN; INCIDENCE; INFECTION RISK; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; ARTHRITIS, RHEUMATOID; COMPARATIVE STUDY; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MEDICARE; OPPORTUNISTIC INFECTIONS; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; TIME; UNITED STATES;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; FEMALE; GLUCOCORTICOIDS; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; MALE; MEDICARE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UNITED STATES;

EID: 84928553933     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22470     Document Type: Article

References (20)

1. Cohen JI., Clinical practice: herpes zoster. N Engl J Med 2013; 369: 255-63.
2. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-α agents. JAMA 2009; 301: 737-44.
3. Yawn BP, Itzler RF, Wollan PC, Pellissier JM, Sy LS, Saddier P., Health care utilization and cost burden of herpes zoster in a community population. Mayo Clin Proc 2009; 84: 787-94.
4. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS., A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007; 82: 1341-9.
5. Gnann JW Jr, Whitley RJ., Clinical practice: herpes zoster. N Engl J Med 2002; 347: 340-6.
6. Galloway JB, Mercer LK, Moseley A, Dixon WG, Ustianowski AP, Helbert M, et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2013; 72: 229-34.
7. Kim SY, Servi A, Polinski JM, Mogun H, Weinblatt ME, Katz JN, et al. Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Res Ther 2011; 13: R32.
8. MacLean CH, Park GS, Traina SB, Liu HH, Hahn BH, Paulus HE, et al. Positive predictive value (PPV) of an administrative data-based algorithm for the identification of patients with rheumatoid arthritis (RA) [abstract]. Arthritis Rheum 2001; 44: S106.
9. Singh JA, Holmgren AR, Noorbaloochi S., Accuracy of Veterans Administration databases for a diagnosis of rheumatoid arthritis. Arthritis Rheum 2004; 51: 952-7.
10. Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011; 306: 2331-9.
11. Donahue JG, Choo PW, Manson JE, Platt R., The incidence of herpes zoster. Arch Intern Med 1995; 155: 1605-9.
12. Mullooly JP, Riedlinger K, Chun C, Weinmann S, Houston H., Incidence of herpes zoster, 1997-2002. Epidemiol Infect 2005; 133: 245-53.
13. Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 2013; 309: 887-95.
14. Eicheldinger C, Bonito A., More accurate racial and ethnic codes for Medicare administrative data. Health Care Financ Rev 2008; 29: 27-42.
15. Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012; 308: 43-9.
16. Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A., Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up. Int J Rheum Dis 2012; 15: 330-5.
17. Centers for Disease Control and Prevention. Adult vaccination coverage: United States, 2010. MMWR Morb Mortal Wkly Rep 2012;61:66-72. URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6104a2.htm.
18. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625-39.
19. Toyama N, Shiraki K, Society of the Miyazaki Prefecture D. Epidemiology of herpes zoster and its relationship to varicella in Japan: a 10-year survey of 48,388 herpes zoster cases in Miyazaki prefecture. J Med Virol 2009; 81: 2053-8.
20. Langan SM, Smeeth L, Margolis DJ, Thomas SL., Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med 2013; 10: e1001420.